- In February 2024, In-Med AI introduced NeuroShield CT, an AI-based neurotrauma screening and quantification tool. This technology assists neuro-critical teams in identifying and quantifying pathologies associated with TBI cases, ensuring accurate and expedited results by automating manual image processing. NeuroShield CT equips radiologists, neurologists, and neurosurgeons with precise data, enabling informed decisions regarding workflow prioritization and acute triage management
- In 2024, The University of California, San Francisco launched a clinical trial, evaluating the effectiveness of repurposed drugs—atorvastatin calcium, candesartan cilexetil, and minocycline hydrochloride—for mild to moderate TBI treatment. The study plans to enroll 672 patients over four years, with preliminary results indicating a 30% improvement in neuroinflammation reduction compared to traditional treatments
- In 2024, Stemedica Cell Technologies commenced clinical trials for a novel stem cell therapy targeting TBI recovery. Early trials revealed that patients receiving this therapy showed a 25% improvement in cognitive function and motor skills. The company projects a 60% increase in patient enrollment in the coming months due to growing demand for regenerative medicine solution
- In 2023, BrainScope Company Inc. introduced a new handheld device., that enhances the accuracy of TBI diagnosis by 40%. Emergency departments utilizing this device reported a 25% decrease in misdiagnosed TBI cases. The adoption rate for this technology increased by 50% across U.S. trauma centers within the first year of its launch
- In 2023, the U.S. Food and Drug Administration approved NeuroSTAT, a neuroprotective agent designed for the treatment of severe traumatic brain injury. Clinical trials demonstrated a 35% reduction in neuronal damage among patients receiving NeuroSTAT compared to a placebo group. This approval is expected to impact a significant portion of the annual 2.8 million TBI cases in the U.S.
